EHA 2023 | Long-term outcomes of patients with CLL treated with continuous ibrutinib
Thomas Kipps
• 9 Jun 2023
Thomas Kipps, MD, PhD, UC San Diego, Moores Cancer Center, La Jolla, CA, comments on the long-term outcomes of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. It has been reported that patients who have been able to maintain therapy on ibrutinib have a long-term survival that is comparable to healthy age-matched controls. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
